Insider Buying: Kane Biotech Inc. (CVE:KNE) Director Acquires C$200,000.00 in Stock

Kane Biotech Inc. (CVE:KNE) Director Marc Edwards acquired 2,000,000 shares of the business’s stock in a transaction that occurred on Friday, January 17th. The shares were acquired at an average cost of C$0.10 per share, for a total transaction of C$200,000.00.

Kane Biotech Stock Down 4.5 %

Shares of CVE KNE opened at C$0.11 on Friday. The stock’s fifty day simple moving average is C$0.11 and its two-hundred day simple moving average is C$0.13. Kane Biotech Inc. has a 12-month low of C$0.08 and a 12-month high of C$0.17. The company has a current ratio of 0.82, a quick ratio of 0.39 and a debt-to-equity ratio of 1,164.24. The stock has a market capitalization of C$13.91 million, a PE ratio of -3.50 and a beta of 0.52.

About Kane Biotech

Kane Biotech Inc, a biotechnology company, engages in the research, development, and commercialization of technologies and products that prevent and remove microbial biofilms in Canada and internationally. The company develops its products using coactiv+ technology, an antimicrobial wound gel platform; and DispersinB technology, a naturally occurring enzyme that cleaves the bacterial surface polysaccharide poly-b-1, 6-N-acetylglucosamine for treating wounds and otic infections.